Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Withdrawn 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Pancreatic Neoplasms 8Neoplasms 5Non-Muscle Invasive Bladder Neoplasms 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Uterine Cervical Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Platinum-resistant Ovarian Cancer 1Pharmacokinetics 1Multiple Myeloma 1Microsatellite Instability 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1

Interventions

pembrolizumab 75Carboplatin 46Paclitaxel 44130-nm albumin-bound paclitaxel 35Gemcitabine 34Cyclophosphamide 23Capecitabine 22Nivolumab 21Albumin-Bound Paclitaxel 21atezolizumab 20sacituzumab govitecan 14spartalizumab 13Doxorubicin 11olaparib 9Cisplatin 9Bevacizumab 9eribulin 8fludarabine 7durvalumab 7avelumab 7Injections 7Fulvestrant 7Fluorouracil 7Vinorelbine 6Leucovorin 6Docetaxel 6iniparib 5budigalimab 5Ipilimumab 5Epirubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Triple Negative Breast Neoplasms × ALT-803 × Clear all
NCT03175666 2025-02-21

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Breast

Triple Negative Breast Neoplasms

NCT03554109 2025-02-21

TNBC

ImmunityBio, Inc.

Phase 2 Withdrawn
Breast

Triple Negative Breast Neoplasms

NCT03387085 2024-08-09

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

ImmunityBio, Inc.

Phase 1/2 Terminated
9 enrolled 18 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡